Compare NRC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRC | ETON |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 683.7M |
| IPO Year | 1997 | 2018 |
| Metric | NRC | ETON |
|---|---|---|
| Price | $16.89 | $25.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 72.9K | ★ 465.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | ★ 4707.69 | N/A |
| EPS | ★ 50.00 | N/A |
| Revenue | ★ $119,686,000.00 | $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | $0.33 | ★ N/A |
| Revenue Growth | 1.81 | ★ 104.94 |
| 52 Week Low | $9.76 | $13.09 |
| 52 Week High | $22.79 | $27.19 |
| Indicator | NRC | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 51.66 | 68.66 |
| Support Level | $16.64 | $16.79 |
| Resistance Level | $18.29 | N/A |
| Average True Range (ATR) | 0.75 | 1.31 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 35.69 | 73.61 |
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.